Drug Metabolism May Be Suppressed in Patients With Inflammatory Conditions
Suppressed drug metabolism was identified in patients with various inflammatory conditions.
Suppressed drug metabolism was identified in patients with various inflammatory conditions.
Colonoscopies decreased by 45% in 2020 compared with averages in 2018 through 2019; 29% decrease seen in prostate biopsies
Except for rituximab, no increased risk seen for in-hospital death or mechanical ventilation for those on long-term immunosuppressive therapy
Odds of participation up for Blacks, Hispanics in breast, lung, prostate cancer trials in 2015 to 2019 compared with 2000 to 2004
Fasting-mimicking diets induce metabolic and immunologic changes that might enhance the effects of standard antineoplastic therapy
Annualized net out-of-pocket costs were highest in the initial and end-of-life phases, lowest in continuing care phase
Lower prevalence of screening for unemployed adults was no longer seen after accounting for health insurance coverage
Population-attributable fraction varied from 3.9% for urinary bladder cancer to 16.9% for stomach cancer
For patients hospitalized with COVID-19, prostate cancer was the most common cancer type across all databases.
Intraoperative administration of dexamethasone linked to reduced 90-day mortality after surgery to remove solid tumors